Table 2

Main clinical outcomes after LDTSCP and phacoemulsification in all patients

Time1 day before LDTSCP1 day after LDTSCP7 days after LDTSCP1 month after phacoemulsificationLast follow-upP value
IOP (mm Hg; median, range)41.5 (33–54)15 (6–28)15 (10–26)11.5 (8–21)13 (11–17)<0.001*
logMAR VA (median, range)CF (LP−1)1.5 (LP−0.3)1.4 (LP−0.3)0.7 (1.7–0.1)0.7 (1.7–0.1)<0.001*
No. of Meds (median, range)5 (3–5)00 (0–3)00<0.001*
No. of eyes with SCE (grade 0/1/2/3)20/0/0/04/9/5/25/13/2/020/0/0/020/0/0/0
ACD (mm; median, range)1.508 (1.090–2.037)1.675 (1.333–2.060)1.713 (1.286–2.057)3.599 (3.338–3.913)3.598 (3.449–3.945)<0.001*
VCDR (median, range)0.65 (0.3–0.9)0.8 (0.5–0.9)0.8 (0.7–0.9)0.010*
Degrees of occluded angle (degree, median, range)360300 (0–360)240 (0–330)240 (0–330)<0.001*
  • *Statistical significance.

  • ACD, anterior chamber depth; CF, count finger; IOP, intraocular pressure; LDTSCP, low-dose transscleral cyclophotocoagulation; LP, light perception; Meds, medications; VA, visual acuity; VCDR, vertical cupto-disc ratio.